Skip to main content
. Author manuscript; available in PMC: 2016 Jan 29.
Published in final edited form as: Vaccine. 2014 Dec 19;33(5):686–692. doi: 10.1016/j.vaccine.2014.11.057

Figure 2. Protective properties of the nanoparticle glycoconjugate glanders vaccine.

Figure 2

(A) Survival of NHPs immunized with AuNP glycoconjugate vaccine or PBS and challenged with B. mallei ATCC 23344. Bacterial burden in the bronchoalveolar lavage (B), bronchial lymph nodes (C), lung (D), spleen (E) and liver (F) of vaccinated and sham NHPs. Anti-LPS (G) and anti-FliC (H) specific serum IgG at days 0 and 80 post-immunization. Groups of 6 NHPs received AuNP glycoconjugate vaccine or PBS, along with alhydrogel as adjuvant. The results are expressed as means ± the standard deviations (SD) of triplicate values.